达拉非尼联合曲美替尼与多靶点酪氨酸激酶抑制剂二线治疗 BRAF V600E突变放射性碘难治性晚期甲状腺癌的疗效
陈光亮 , 何霞云 , 黄乃思 , 陈嘉莹 , 桑友洲 , 杨亚男 , 沈春英 , 王玉龙 , 王宇 , 季冬梅
中国医科大学学报 ›› 2026, Vol. 55 ›› Issue (10) : 865 -870.
达拉非尼联合曲美替尼与多靶点酪氨酸激酶抑制剂二线治疗 BRAF V600E突变放射性碘难治性晚期甲状腺癌的疗效
Efficacy of dabrafenib plus trametinib and multitargeted tyrosine kinase inhibitor as second-line therapy for BRAF V600E-mutant radioactive iodine-refractory advanced thyroid cancer
目的 比较达拉非尼联合曲美替尼 (D+T) 与多靶点酪氨酸激酶抑制剂 (TKI) 作为二线治疗在放射性碘难治性晚期甲状腺癌患者中的疗效,分析基因突变对疗效的潜在影响。方法 收集接受以D+T方案或TKI方案为基础的二线治疗的BRAF V600E突变放射性碘难治性晚期甲状腺癌患者39例 (含9例低分化型甲状腺癌),其中D+T组30例,TKI组9例。采用倾向性评分重叠加权法控制混杂偏倚,比较2组患者中位无进展生存期 (PFS) 的差异。结果 经重叠加权后,2组患者基线特征达到均衡。D+T组中位PFS为13.3个月 (95%CI:6.7~19.9),TKI组为3.5个月 (95%CI:1.8~5.2)。加权Cox回归和随访时间截至30个月的敏感性分析结果均显示,D+T组进展或死亡风险呈降低趋势 (HR分别为0.613和0.650)。探索性分析结果显示,D+T方案的PFS获益仅在无TERT启动子、TP53和PI3K/AKT通路相关基因突变患者中显著 (HR<1),在基因突变患者中未显示明显获益。结论 在放射性碘难治性晚期甲状腺癌患者的二线治疗中,D+T方案较TKI方案显示出更长的中位PFS,伴随基因突变可能影响PFS获益。D+T方案可能为更优的二线治疗选择。
Objective To compare the efficacy of dabrafenib plus trametinib (D+T) with multitargeted tyrosine kinase inhibitor (TKI) as second-line therapy for BRAF V600E-mutant radioactive iodine-refractory advanced thyroid cancer,and to explore the potential impact of coexisting gene mutations on efficacy. Methods We retrospectively analyzed 39 patients with BRAF V600E-mutant radioactive iodine-refractory advanced thyroid cancer,including nine with poorly differentiated thyroid cancer. The patients received D+T-based (n = 30) or TKI-based (n = 9) second-line therapy. Propensity score overlap weighting was used to adjust confounding factors,and progression-free survival (PFS) was compared between groups. Results After overlap weighting,baseline characteristics were balanced between groups. Median PFS was 13.3 months (95%CI:6.7-19.9) in the D+T group and 3.5 months (95%CI:1.8-5.2) in the TKI group. Both weighted Cox regression and sensitivity analysis with follow-up truncated at 30 months showed a trend toward reduced risk of progression or death with D+T-based therapy,with hazard ratio (HR) of 0.613 and 0.650,respectively. Exploratory analyses revealed that the PFS benefit of D+T was apparent only in patients without TERT promoter,TP53,or PI3K/AKT pathway-related gene mutations,but not in those with these mutations. Conclusion In second-line therapy for radioactive iodine-refractory advanced thyroid cancer,D+T therapy showed longer median PFS than TKI therapy,and this benefit may be influenced by coexisting gene mutations. Overall,D+T therapy may represent a more favorable second-line option than TKI therapy.
| [1] |
|
| [2] |
|
| [3] |
|
| [4] |
Díaz Vico T, |
| [5] |
|
| [6] |
|
| [7] |
Araque K A,Gubbi S,Klubo-Gwiezdzinska J. Updates on the management of thyroid cancer [J].Horm Metab Res,2020,52 (8):562-577. DOI:10.1055/a-1089-7870. |
| [8] |
|
| [9] |
|
| [10] |
|
| [11] |
|
| [12] |
|
“癌症、心脑血管、呼吸和代谢性疾病防治研究”国家科技重大专项(2026ZD0553100)
/
| 〈 |
|
〉 |